Eli Lilly Signs $2.75 Billion AI Drug Discovery Deal with Insilico Medicine
Eli Lilly has inked a deal worth up to $2.75 billion with AI pharma firm Insilico Medicine to develop and commercialize AI-discovered oral drugs globally.
Eli Lilly has inked a deal worth up to $2.75 billion with AI pharma firm Insilico Medicine to develop and commercialize AI-discovered oral drugs globally.